Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 165

1.

Increased prevalence of vulnerable atherosclerotic plaques and low levels of natural IgM antibodies against phosphorylcholine in patients with systemic lupus erythematosus.

Anania C, Gustafsson T, Hua X, Su J, Vikström M, de Faire U, Heimbürger M, Jogestrand T, Frostegård J.

Arthritis Res Ther. 2010;12(6):R214. doi: 10.1186/ar3193. Epub 2010 Nov 23.

2.

IgM antibodies against malondialdehyde and phosphorylcholine are together strong protection markers for atherosclerosis in systemic lupus erythematosus: Regulation and underlying mechanisms.

Rahman M, Sing S, Golabkesh Z, Fiskesund R, Gustafsson T, Jogestrand T, Frostegård AG, Hafström I, Liu A, Frostegård J.

Clin Immunol. 2016 May;166-167:27-37. doi: 10.1016/j.clim.2016.04.007. Epub 2016 Apr 19.

PMID:
27102765
3.

Low levels of antibodies against oxidized but not nonoxidized cardiolipin and phosphatidylserine are associated with atherosclerotic plaques in systemic lupus erythematosus.

Su J, Frostegård AG, Hua X, Gustafsson T, Jogestrand T, Hafström I, Frostegård J.

J Rheumatol. 2013 Nov;40(11):1856-64. doi: 10.3899/jrheum.121173. Epub 2013 Sep 15.

PMID:
24037548
5.

Relation of carotid plaque with natural IgM antibodies in patients with systemic lupus erythematosus.

Grönwall C, Reynolds H, Kim JK, Buyon J, Goldberg JD, Clancy RM, Silverman GJ.

Clin Immunol. 2014 Jul;153(1):1-7. doi: 10.1016/j.clim.2014.03.017. Epub 2014 Apr 3.

6.

Excess atherosclerosis in systemic lupus erythematosus,-A matter of renal involvement: Case control study of 281 SLE patients and 281 individually matched population controls.

Gustafsson JT, Herlitz Lindberg M, Gunnarsson I, Pettersson S, Elvin K, Öhrvik J, Larsson A, Jensen-Urstad K, Svenungsson E.

PLoS One. 2017 Apr 17;12(4):e0174572. doi: 10.1371/journal.pone.0174572. eCollection 2017.

7.
9.

Natural antibodies against phosphorylcholine as potential protective factors in SLE.

Su J, Hua X, Concha H, Svenungsson E, Cederholm A, Frostegård J.

Rheumatology (Oxford). 2008 Aug;47(8):1144-50. doi: 10.1093/rheumatology/ken120. Epub 2008 Jun 3. Erratum in: Rheumatology (Oxford). 2008 Oct;47(10):1593.

PMID:
18522961
10.

Systemic lupus erythematosus: the influence of disease-related and classical risk factors on intima media thickness and prevalence of atherosclerotic plaques--a preliminary report. Beneficial effect of immunosuppressive treatment on carotid intima media thickness.

Kisiel B, Kruszewski R, Juszkiewicz A, Raczkiewicz A, Bachta A, Kłos K, Duda K, Saracyn M, Szymański K, Młozniak-Cieśla A, Grabowska-Jodkowska A, Olesińska M, Bogusławska-Walecka R, Niemczyk S, Płoski R, Tłustochowicz W.

Acta Cardiol. 2015 Apr;70(2):169-75.

PMID:
26148377
11.

Progression of carotid intima-media thickness and plaque in women with systemic lupus erythematosus.

Thompson T, Sutton-Tyrrell K, Wildman RP, Kao A, Fitzgerald SG, Shook B, Tracy RP, Kuller LH, Brockwell S, Manzi S.

Arthritis Rheum. 2008 Mar;58(3):835-42. doi: 10.1002/art.23196.

12.

Risk factors for cardiovascular disease in systemic lupus erythematosus.

Svenungsson E, Jensen-Urstad K, Heimbürger M, Silveira A, Hamsten A, de Faire U, Witztum JL, Frostegård J.

Circulation. 2001 Oct 16;104(16):1887-93.

13.

Antibodies of IgM subclass to phosphorylcholine and oxidized LDL are protective factors for atherosclerosis in patients with hypertension.

Su J, Georgiades A, Wu R, Thulin T, de Faire U, Frostegård J.

Atherosclerosis. 2006 Sep;188(1):160-6. Epub 2005 Nov 22.

PMID:
16307748
14.

Auto-antibodies do not influence development of atherosclerotic plaques in rheumatoid arthritis.

Pereira I, Laurindo I, Burlingame R, Anjos L, Viana V, Leon E, Vendramini M, Borba E.

Joint Bone Spine. 2008 Jul;75(4):416-21. doi: 10.1016/j.jbspin.2008.01.022. Epub 2008 May 23.

PMID:
18457983
15.

Anti-ox-LDL antibodies and anti-ox-LDL-B2GPI antibodies in patients with systemic lupus erythematosus.

Nowak B, Szmyrka-Kaczmarek M, Durazińska A, Płaksej R, Borysewicz K, Korman L, Wiland P.

Adv Clin Exp Med. 2012 May-Jun;21(3):331-5.

16.

Low levels of IgM antibodies against phosphorylcholine are associated with fast carotid intima media thickness progression and cardiovascular risk in men.

Gigante B, Leander K, Vikström M, Baldassarre D, Veglia F, Strawbridge RJ, McLeod O, Gertow K, Sennblad B, Shah S, Zabaneh D, Humphries SE, Kauhanen J, Rauramaa R, Smit AJ, Mannarino E, Giral P, Tremoli E, Hamsten A, Frostegård J, de Faire U; IMPROVE Study Group.

Atherosclerosis. 2014 Oct;236(2):394-9. doi: 10.1016/j.atherosclerosis.2014.07.030. Epub 2014 Aug 5.

PMID:
25150937
17.

Antibodies against native and oxidized cardiolipin and phosphatidylserine and phosphorylcholine in atherosclerosis development.

Frostegård AG, Su J, Hua X, Vikström M, de Faire U, Frostegård J.

PLoS One. 2014 Dec 4;9(12):e111764. doi: 10.1371/journal.pone.0111764. eCollection 2014.

18.

A panel of biomarkers is associated with increased risk of the presence and progression of atherosclerosis in women with systemic lupus erythematosus.

McMahon M, Skaggs BJ, Grossman JM, Sahakian L, Fitzgerald J, Wong WK, Lourenco EV, Ragavendra N, Charles-Schoeman C, Gorn A, Karpouzas GA, Taylor MB, Watson KE, Weisman MH, Wallace DJ, Hahn BH.

Arthritis Rheumatol. 2014 Jan;66(1):130-9. doi: 10.1002/art.38204.

19.

Decreased binding of annexin v to endothelial cells: a potential mechanism in atherothrombosis of patients with systemic lupus erythematosus.

Cederholm A, Svenungsson E, Jensen-Urstad K, Trollmo C, Ulfgren AK, Swedenborg J, Fei GZ, Frostegård J.

Arterioscler Thromb Vasc Biol. 2005 Jan;25(1):198-203. Epub 2004 Nov 11.

20.

Platelet-activating factor-acetylhydrolase and other novel risk and protective factors for cardiovascular disease in systemic lupus erythematosus.

Cederholm A, Svenungsson E, Stengel D, Fei GZ, Pockley AG, Ninio E, Frostegård J.

Arthritis Rheum. 2004 Sep;50(9):2869-76.

Supplemental Content

Support Center